DaVita Inc. $DVA Holdings Lifted by Doma Perpetual Capital Management LLC

Key Points

• Doma Perpetual Capital Management LLC significantly increased its stake in DaVita Inc. by 172.3% during the first quarter, holding 288,360 shares valued at approximately $44.11 million.
• Analyst ratings for DaVita have varied, with Barclays reducing its target price from $169 to $160 while Wall Street Zen upgraded it from "hold" to "buy," contributing to a consensus target price of $164.00.
• DaVita's recent quarterly earnings exceeded estimates, reporting $2.95 EPS against a forecast of $2.70, alongside a year-over-year revenue increase of 6.1%.

Doma Perpetual Capital Management LLC grew its position in DaVita Inc. (NYSE:DVA - Free Report) by 172.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288,360 shares of the company's stock after buying an additional 182,476 shares during the period. DaVita accounts for approximately 17.3% of Doma Perpetual Capital Management LLC's investment portfolio, making the stock its 2nd largest position. Doma Perpetual Capital Management LLC owned 0.38% of DaVita worth $44,110,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Invesco Ltd. boosted its position in shares of DaVita by 3.4% during the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock worth $251,322,000 after purchasing an additional 53,402 shares during the period. Northern Trust Corp boosted its position in shares of DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock worth $136,240,000 after purchasing an additional 149,858 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of DaVita by 14.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after purchasing an additional 57,386 shares during the period. Epoch Investment Partners Inc. boosted its position in shares of DaVita by 10.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company's stock worth $62,400,000 after purchasing an additional 39,485 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of DaVita by 35.2% during the 4th quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock worth $58,687,000 after purchasing an additional 102,230 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Stock Up 0.2%

Shares of DVA traded up $0.21 during midday trading on Thursday, reaching $136.18. The stock had a trading volume of 245,216 shares, compared to its average volume of 852,014. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The company's fifty day simple moving average is $139.59 and its two-hundred day simple moving average is $142.20. The company has a market cap of $9.74 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 0.99 and a beta of 1.13. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period last year, the business earned $2.00 EPS. The company's revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on DVA shares. Truist Financial set a $148.00 price objective on shares of DaVita in a research report on Friday, August 8th. Barclays lowered their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, August 22nd. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $164.00.

Insider Buying and Selling at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.